Tartalom
Congressus Pharmaceuticus Hungaricus XVI.
Továbbképző közlemények
-
Mirzahosseini Arash: A mágneses magrezonancia és gyógyszerészeti vonatkozásai – GYOGAI. 63. 646-653. 2019.
Irodalom
1. Keeler, J. (szerk.): Understanding NMR spectroscopy, 2. kiadás. John Wiley & Sons, 2010.
2. de Graaf, R. A. (szerk.): In vivo NMR spectroscopy, 2. kiadás. John Wiley & Sons, 2007.
3. Schoenberger, T.: Validation of quantitative NMR methods, Bundeskriminalamt, 2012.
Mirzahosseini Arash: Pharmaceutical applications of nuclear magnetic resonance
Nuclear magnetic resonance is the underlying pheno-menon of NMR and MRI, which have become the indispensable methods of the natural and life sciences, therefore judged the discussion of the pharmaceutical application of these methods to be of high importance. We can see via the mode of action of the NMR device how the signal is acquired, and why this method is the most valuable in the structure elucidation of molecules used in pharmaceutical research and development. NMR can also be used in quantitative assays, lending itself to the quality control of pharmaceutics. Finally, we see how MRI and the closely related in vivo NMR have become crucial in diagnostic imaging and biomedical research.
-
Erős Petra, Horváth Beáta: Korszerű fogamzásgátlás: II. – Nem orális fogamzásgátlók – GYOGAI. 63. 654-657. 2019.
Irodalom
1. https://emedicine.medscape.com/article/258507-overview#a1
2. IQWiG (Institute for Quality and Efficiency in Health Care) Contraception: Hormonal contraceptives; Created: October 29, 2008; Last Update: June 29, 2017.
3. https://www.nhs.uk/conditions/contraception/contraceptive-patch/
4. Galzote, R.M. et al: Int J Womens Health. 9, 315–321 (2017).
5. Feisullin, K., Westhoff, C.: in Principles of Gender-Specific Medicine (Second Edition), Transdermal Patch, Contraception, 2010.
6. Palmer, S.N. et al: Rev Obstet Gynecol. 2(2), 84–92 (2009, Spring).
7. Pastore, M.N. et al; Br J Pharmacol. 172(9), 2179–2209 (2015).
8. https://www.medicines.org.uk/emc/product/6794/smpc
9. https://www.ema.europa.eu/en/documents/product-information/evra-epar-product-information_hu.pdf
10. https://www.ogyei.gov.hu/gyogyszeradatbazis&action=show_details&item=21825
11. Brache et al: Contraception. 82(5), 418-27 (2010). doi: 10.1016/j.contraception.
12. Progering Product Brief: https://path.azureedge.net/media/documents/RHSC_progesterone_br.pdf
13. https://pipeline.ctiexchange.org/products/progering
14. http://www.nhs.uk/Conditions/contraception-guide/Pages/what-is-contraception.aspx;
15. Jacobstein R. et al: Progestin-only contraception: Injectables and implants https://doi.org/10.1016/j.bpobgyn.2014.05.003
16. McNaught J. et al: Adolesc Med Clin. 16(3), 495-515 (2005).
17. https://www.drugs.com/depo-provera.html; http://www.webmd.com/sex/birth-control/ss/slideshow-birth-control-options;
18. https://www.medicines.org.uk/emc/product/5720/smpc
19. http://womenshealthwise.com/gynecology/birth-control-methods/#.WAjThU8cSUk;
20. http://www.webmd.com/sex/birth-control/subdermal-implant-for-birth-control
21. https://www.medicines.org.uk/emc/product/6721/smpc
22. Pradhan S., et al: J. Pediatr. Adolesc. Gynecol. 32(5), S23-S29 (2019).
23. SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN)
24. XuXiong et al: IUD use and the risk of ectopic pregnancy: A meta-analysis of case-control studies, Contraception Volume 52, Issue 1, July 1995, Pages 23-34.
25. https://www.bayer.co.za/static/documents/MSDS/PIs/NOVA_T_380_EN_PI.pdf
26. https://www.medicines.org.uk/emc/product/1132/smpc
27. Goldstuck, N.D. et al: Gynaecol.Forum 29(1), 4-8, (2019).
28. Apter, D.: J. Pediatr. Adolesc. Gynecol. 32(5) S36-S42 (2019).
Erős P., Horváth B.: Modern contraception: II. Nonoral contraceptives
Prevention of pregnancy was always a major issue in human life but the effective and safe methods were not developed until the 20th Century when condoms and hormonal contraceptives discovery opened a new era in the field of contraception. Today there are several methods including natural family planning, barrier and hormonal methods and the route of administration of hormonal products were expanded from oral use to vaginal, intradermal, transdermal and intrauterine administration. In this article our aim was to summarise the most important characteristics about the available non oral contraceptive methods, explain the potential advantages, and disadvantages compared to other modern oral contraceptives. Due to the wide variety of hormonal contraceptives, everybody should take into account by the choice that the risk benefit balance should be evaluated seriously.
-
Gyalai Boglárka, Juhász Klaudia, Horváth István László: Az időskori gyógyszerelés problémái – GYOGAI. 63. 658-665 2019.
Irodalom
1. Bor A., Matuz M., Doró P., Viola R., Soós G.: Drug-related problems in the elderly. Orv. Hetil. 153, 1926–1936 (2012).
2. A népesség gyarapodó rétege – Az időskorúak jellemzői https://www.ksh.hu/docs/hun/xftp/idoszaki/pdf/nepesseg_gyarapodo.pdf 2018.11.12. (letöltve: 2019.01.15.)
3. http://www.ksh.hu/docs/hun/xftp/idoszaki/mo/mo2017.pdf 2018.11.12. Magyarország, 2017.
4. Proposed working definition of an older person in Africa for the MDS Project https://www.who.int/healthinfo/survey/ageingdefnolder/en/ (letöltve: 2019.01.15.)
5. Korösszetétel https://www.demografia.hu/hu/tudastar/fogalomtar/12-korosszetetel (letöltve: 2019.01.15.)
6. Colloca, G., Santoro, M., Gambassi, G.: Surg Oncol. 19(3), 124-30 (2010).
7. Klotz, U.: Drug Metab Rev. 41(2), 67-76 (2009).
8. Kvell K., Pongrácz J., Székely M., Balaskó M., Pétervári E., Bakó Gy.: A Gerontológia Molekuláris és Klinikai Alapjai 2011. 4. old.
9. Pavlik G.: Sportélettan Medicina. Könyvkiadó Zrt. 2011, 529-530.
10. Hankó B.: Gyógyszerészet 50, 619–623 (2006).
11. ADHERENCE TO LONG-TERM THERAPIES https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1 (letöltve: 2019.01.22.)
12. Navickas, R., Petric, V.K., Feigl, A.B., Seychell, M.: J Comorb. 17,6 (1) 4-11 (2009).
13. Salive, M.E.: Multimorbidity in Older Adults. 2013 Epidemiologic Reviews, Volume 35, Issue 1, 1 January 2013, Pages 75–83.
14. KSH tájékoztatási adatbázis http://statinfo.ksh.hu/Statinfo/haViewer.jsp (letöltve: 2019.02.15.)
15. Kirchberger, I., Meisinger, C., Heier, M., Zimmermann, A.K., Thorand, B., Autenrieth, C.S., Peters, A., Ladwig, K.H., Döring, A.: A Prospective Cohort Study PLoS One. 7(1), e30556 (2012).
16. Yap, A.F., Thirumoorthy, T., Kwan, Y.H.: Geriatr Gerontol Int. 16(10), 1093-1101 (2016).
17. Bilal Ahmed, Kashmira Nanji, Rakshinda Mujeeb, Muhammad Junaid Patel: Effects of Polypharmacy on Adverse Drug Reactions among Geriatric Outpatients at a Tertiary Care Hospital in Karachi: A Prospective Cohort Study PLoS One. 9(11), (2011).
18. Maher, R.L., Hanlon, J., Hajjar, E.R.: Expert Opin Drug Saf. 13(1), 57-65 (2014).
19. Machado-Alba, J.E., Gaviria-Mendoza. A., Machado-Duque, M.E., Chica, L.: Expert Opin Drug Saf. 16(2), 111-112 (2017).
20. Reamer, L., Bushardt, E., Massey, B., Temple, W., Simpson, Ariail, J.C., Simpson, K.N.: Clin Interv Aging. 3(2), 383–389 (2008).
21. Lee, J., Alshehri, S., Kutbi, H., Martin, J.: Integrated Pharmacy Research and Practice 4(augusztus), 101—111 (2015).
22. Overview of Geriatric Care https://www.msdmanuals.com/professional/geriatrics/provision-of-care-to-the-elderly/overview-of-geriatric-care (letöltve: 2019.02.17.)
23. Kreckman, J., Wasey, W., Wise, S., Stevens, T., Millburg, L., Jaeger, C.: BMJ Open Qual. 7(2), e000281 (2018).
24. Renaudin, P., Boyer, L., Esteve, M.A., Bertault-Peres, P., Auquier, P., Honore, S.: Br J Clin Pharmacol. 82(6), 1660-1673 (2016).
25. Zermansky, A.G., Petty, D.R., Raynor, D.K., Freemantle, N., Vail, A., Lowe, C.J.: BMJ. 323(7325), 1340-3 (2001).
26. Thompson, W., Farrell, B.: Can J Hosp Pharm. 66(3), 201-2 (2013).
27. Creating evidence-based deprescribing guidelines https://deprescribing.org/news/creating-evidence-based-deprescribing-guidelines/ (letöltve: 2019.02.28.)
28. Bella és Begónia https://www.mgyk.hu/bella-es-begonia-mgyk-hu.html 2019.02.27.
29. Kaufmann, C.P., Tremp, R., Hersberger, K.E., Lampert, M.L.: Eur J Clin Pharmacol. 70(1), 1-11 (2014).
30. Page, R.L., Linnebur, S.A., Bryant, L.L., Ruscin, J.M.: Clin Interv Aging. 5, 75-87 (2010).
31. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 63(11), 2227-46 (2015).
Gyalai B., Juhász K., Horváth I. L.: Medication-related problems in aging-adults
Medication-related problems are getting more and more important, due to the aging population of developed countries. Prevalence of chronic diseases and multimorbidity increase substantially with age. This leads to polypharmacy because most of the time, the patients have to combine the different medications which may reduce the patient’s adherence. This can cause decreased efficiency, over- and underdosage and drug interactions. To reduce these drug-related problems, the American Geriatrics Society created the Beers criteria, the first list of the potentially inappropriate medications in elderly (PIM list). I used these lists in order to estimate the drug usage among 215 patient (over 65 year) at a chronic internal medicine department
-
Gajdács Márió: Imipenem/cilasztatin/relebaktám: az új β-laktám-β-laktamáz-gátló kombináció – GYOGAI. 63. 595-600 2019.
Irodalom
1. Gaynes, R.: Emerg. Infect. Dis. 23, 849–853 (2017).
2. World Health Organisation. Antimicrobial Resistance: Global Report on Surveillance. pp. 1–256 (2014). http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1 [2019. 06. 08.]
3. ECDC/EMEA Joint Technical Report (2009). The Bacterial Challenge: Time to React. http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf [2019. 06. 08.]
4. CDC Antibiotic/Antimicrobial Resistance (AR/AMR). https://www.cdc.gov/drugresistance/biggest_threats.html [2019. 06. 08.]
5. O’Neill: J. Antimicrobial Resistance: Tackling aCrisis for theHealth andWealth ofNations. https://amr-review.org/sites/default/files/AMRReviewPaperTacklingacrisisforthehealthandwealthofnation_s1.pdf [2019. 06. 08.]
6. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., et al.: Clin. Microbiol. Infect. 18, 268–281 (2012).
7. Gajdács, M.: Molecules 24, 892 (2019).
8. Brunton, L., Chabner, B.A., Knollman, B.: Goodman & Gillman’s The Pharmacological Basis of Therapeutics, 12th ed.; McGraw-Hill: New York, NY, USA (2011).
9. Nahum, G.G., Uhl, K., Kennedy, D.L.: Obstet. Gynecol. 107, 1120–1138 (2006).
10. Santajit, S., Indrawattana, N.: Biomed. Res. Int. 2016, 2475067 (2016).
11. Bush, K., Jacoby, G.A.: Antimicrob. Agents Chemother. 54, 969-976 (2010).
12. Gajdács, M., Ábrók, M., Lázár, A., Burián, K.: Gyógyszerészet 63, 405-411 (2019).
13. Gajdács, M. Ábrók, M., Lázár, A., Burián K.: Medicina (Kaunas) 55, 356 (2019).
14. Karaiskos, I., Galani, I., Souli, M., Giamarellou, H.: Expert. Opin. Drug Metab. Toxicol. 15, 133–149 (2019).
15. Cantón, R., González-Alba, J.M., Galán, J.C.: Front. Microbiol. 3, 110 (2012).
16. Codjoe, F.S., Donkor, E.S.: Med. Sci. (Basel) 6, 1 (2017).
17. Gajdács, M.: Egészségfejlesztés 60, 31-36 (2019).
18. Gupta, S., Govil, D., Kakar, P.N., Prakash, O., Arora, D., Das, S., Govil, P., Malhotra, A.: Indian J. Crit. Care Med. 13, 49–53 (2009).
19. Zhou, M., Chen, J., Liu, Y., Hu, Y., Liu, Y., Lu, J., Zhang, S., Yu, Y., Huang, X., Yang, Q., et al.: Clin. Infect. Dis. 67, S206–S216 (2018).
20. Lob, S.H., Hackel, M.A., Kazmierczak, K.M., Young, K., Motyl, M.R., Karlowsky, J.A., Sahm, D.F.: Antimicrob. Agents Chemother. 61, e02209-16 (2017).
21. Hirsch, E.B., Ledesma, K.R., Chang, K.T., Schwartz, M.S., Motyl, M.R., Tam, V.H.: Antimicrob. Agents Chemother. 56, 3753-3757 (2012).
22. Recarbrio™ package insert (2019). https://www.merck.com/product/usa/pi_circulars/r/recarbrio/recarbrio_pi.pdf [2019. 06. 08.]
23. Qualified Infectious Diseases Product Designation (2019). https://www.fda.gov/media/111091/download [2019. 06. 08.]
24. Sims, M., Mariyanovski, V., McLeroth, P., Akers, W., Lee, Y.C., Brown, M.L., Du, J., Pedley, A., Kartsonis, N.A., Paschke, A.: J. Antimicrob. Chemother. 72, 2616-2626 (2017).
25. Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M., Rizk, M.L., Brown, M.L., Losada, M.C., Pedley, A., Kartsonis, N.A., Paschke, A.: Antimicrob. Agents Chemother. 60, 6234-43 (2016).
26. Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) (RESTORE-IMI 1) (2018). https://clinicaltrials.gov/ct2/show/NCT02452047 [2019. 06. 08.]
27. Gajdács, M., Urbán, E.: Medicina (Kaunas). 55, 285 (2019).
28. Medina, E., Pieper, D.H.: Curr. Top. Microbiol. Immunol. 398, 3–33 (2016).
Gajdács M.: Imipenem/cilastatin/relebactam (Recarbrio™): a novel β-lactam-β-lactamase-inhibitor combination
β-lactam antibiotics (penicillin derivatives, cephalosporins, carbapenems, monobactams) are considered the backbone of antibacterial pharmacology; these antibiotics are widely used, highly effective agents, that exert their antibacterial activity by binding to and inhibiting the action of penicillin binding proteins (PBPs). In Gram-negative bacteria, the most common form of resistance against β-lactam antibiotics is the production of various β-lactamase enzymes, the most important of which is the production of enzymes capable of degrading carbapenems; these enzymes may be inhibited to various extents by so-called „second generation” β-lactamase-inhibitors (avibactam, relebactam, vaborbactam). Klebsiella species and the non-fermenting Gram-negative Pseudomonas aeruginosa are a serious burden to the clinical practice, as physicians have few therapeutic alternatives to treat these infections. Imipenem/cilastatin/relebactam (Recarbrio™) is a combination of three drug molecules that has been authorized by the Food and Drug Administration (FDA) for the therapy of complicated urinary tract infections and complicated intra-abdominal infections, where limited or no alternative therapy is available. The purpose of this communication is to summarize the data available so far on this new drug combination.
β-lactam antibiotics (penicillin derivatives, cephalosporins, carbapenems, monobactams) are considered the backbone of antibacterial pharmacology; these antibiotics are widely used, highly effective agents, that exert their antibacterial activity by binding to and inhibiting the action of penicillin binding proteins (PBPs). In Gram-negative bacteria, the most common form of resistance against β-lactam antibiotics is the production of various β-lactamase enzymes, the most important of which is the production of enzymes capable of degrading carbapenems; these enzymes may be inhibited to various extents by so-called „second generation” β-lactamase-inhibitors (avibactam, relebactam, vaborbactam). Klebsiella species and the non-fermenting Gram-negative Pseudomonas aeruginosa are a serious burden to the clinical practice, as physicians have few therapeutic alternatives to treat these infections. Imipenem/cilastatin/relebactam (Recarbrio™) is a combination of three drug molecules that has been authorized by the Food and Drug Administration (FDA) for the therapy of complicated urinary tract infections and complicated intra-abdominal infections, where limited or no alternative therapy is available. The purpose of this communication is to summarize the data available so far on this new drug combination.
Keywords: imipenem, cilastatin, relebactam, β-lactams, Klebsiella, Pseudomonas, MDR
Aktuális oldalak
-
Javaslatok a szakgyógyszerész-képzés szabályozásának módosítására – GYOGAI. 63. 643-645. 2019.
Irodalom
–
Hírek
Beszámoló a 8Th BBBB Konferenciáról – Középpontban az adherencia, Hungaromed 2019. október 9. – IV. Hargita Megyei Gyógyszerész Napok – Hírek (nem csak) Szegedről – Ács Kamilla PhD védése – Bogdán Dóra PhD védése – Veszelyné Kotán Edit PhD védése – Vida Róbert György PhD védése – Inmemoriam
